{"id":397399,"date":"2025-09-04T13:58:16","date_gmt":"2025-09-04T13:58:16","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/397399\/"},"modified":"2025-09-04T13:58:16","modified_gmt":"2025-09-04T13:58:16","slug":"germany-as-europes-beacon-how-enua-is-securing-medical-cannabis-amid-legalisation-shifts","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/397399\/","title":{"rendered":"Germany as Europe\u2019s Beacon: How Enua Is Securing Medical Cannabis\u00a0 Amid Legalisation Shifts"},"content":{"rendered":"

In the latest instalment of our series spotlighting the expert contributors to Prohibition Partners\u2019 newly launched Insights Hub<\/a>, we sat down with Enua to discuss the risks posed by Germany\u2019s shifting focus towards recreational reform, the company\u2019s proposals for strengthening pharmacy-led distribution and introducing over-the-counter cannabis products, and its long-term mission to ensure continuity of care for hundreds of thousands of patients across Germany.<\/p>\n

\"\"<\/a><\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

With the partial legalisation of cannabis on April 1, 2024, Germany made its long-anticipated move. It was the right step \u2013 symbolically, politically, and socially. Despite legislative advancements, patients continue to face administrative challenges and uncertainties in accessing medical cannabis, highlighting the need for streamlined processes and clear guidelines.<\/p>\n

This is not acceptable.\u00a0<\/strong><\/p>\n

Germany does not need debates that look backwards and risk undermining patient well-being. It requires forward-thinking solutions \u2013 bold yet responsible measures that ensure uninterrupted, safe access to cannabis-based medicines. That is precisely where enua comes in.<\/p>\n

A Stabilising Force in a Shifting Landscape\u00a0<\/strong><\/p>\n

Germany\u2019s medical cannabis infrastructure has taken years to build. It is a complex yet functioning system involving physicians, health insurers, licensed pharmacies, and pharmaceutical distributors. But the current shift toward recreational cannabis reform \u2013 including legal home cultivation and planned adult-use pilot programs \u2013 risks drawing focus and resources away from the medical cannabis systems, unless safeguards are put in place.<\/p>\n

At Enua, we are not chasing hype \u2013 we are building continuity. Our company connects the dots between demand and delivery, ensuring that patients, pharmacists, and prescribers remain in sync, even as the policy environment evolves.<\/p>\n

\u00a0<\/p>\n

\"\"<\/a><\/p>\n

Medical Access Must Not Be a Casualty of Legalisation\u00a0<\/strong><\/p>\n

Legalisation should not come at the cost of patient care. Unfortunately, in many jurisdictions, that\u2019s precisely what happened. Germany must do better. With an estimated 200.000 medical cannabis patients and an additional estimated 600.000 self-paying consumers, Germany\u2019s legal cannabis system today serves nearly 800.000\u00a0 individuals \u2013 and their access cannot be left to chance.<\/p>\n

We\u2019re seeing this tension play out in real time: overwhelmed doctors, pharmacy stockouts, and rising confusion about what\u2019s medical, what\u2019s recreational, and what\u2019s simply unavailable. That\u2019s why we advocate for solutions like an over-the-counter (OTC)\u00a0 product with a moderate THC content \u2013 around 10%. It would offer relief for many common conditions like insomnia, anxiety, and chronic pain, while reducing pressure on physicians and preserving clinical oversight via pharmacies.<\/p>\n

The Pharmacy: Not Just a Sales Point\u2014A Safety Net\u00a0<\/strong><\/p>\n

In Germany, pharmacies are not retail spaces. They are trusted healthcare institutions.\u00a0 This makes them the ideal access point for sensitive substances like cannabis.\u00a0 Pharmacists ensure proper usage, verify quality, and educate patients\u2014functions that neither black markets nor recreational outlets can reliably provide.<\/p>\n

By anchoring medical cannabis distribution in pharmacies, Germany reinforces trust,\u00a0 quality, and accessibility. enua\u2019s logistics and compliance systems are designed around\u00a0this model, offering real-time inventory, traceability, and accountability across the supply chain.<\/p>\n

\"\"<\/a><\/p>\n

A European Model in the Making\u00a0<\/strong><\/p>\n

What Germany does next will resonate far beyond its borders. European nations are closely observing whether Germany can manage both liberalisation and medical continuity. The opportunity is immense: to lead not just with policy but with infrastructure, integrity, and patient outcomes.<\/p>\n

enua is committed to supporting that vision. Our systems are scalable, our partners are ready, and our mission is clear: to safeguard medical access during a moment of unprecedented transformation.<\/p>\n

Now Is the Time to Act\u00a0<\/strong><\/p>\n

Patients are waiting. Pharmacies are prepared. The industry stands ready. What we need now is legal clarity and political courage. Germany has the infrastructure to lead\u00a0 Europe\u2014but leadership means more than legislation. It means delivery. Medical cannabis is not a political symbol. It is healthcare. And in times of change,\u00a0 health must come first.<\/p>\n","protected":false},"excerpt":{"rendered":"In the latest instalment of our series spotlighting the expert contributors to Prohibition Partners\u2019 newly launched Insights Hub,…\n","protected":false},"author":2,"featured_media":397400,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5310],"tags":[137205,137206,137207,137208,2000,299,137209,137210,137211,137212,137213,1824,137214,137215,137216,137217],"class_list":{"0":"post-397399","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-germany","8":"tag-cannabis-healthcare-germany","9":"tag-cannabis-patient-access-germany","10":"tag-cannabis-pharmacy-distribution-germany","11":"tag-enua-medical-cannabis","12":"tag-eu","13":"tag-europe","14":"tag-european-cannabis-legalisation","15":"tag-german-cannabis-infrastructure","16":"tag-german-cannabis-patients","17":"tag-german-cannabis-reform","18":"tag-german-pharmacies-cannabis","19":"tag-germany","20":"tag-germany-cannabis-legalisation-2024","21":"tag-germany-medical-cannabis-access","22":"tag-medical-cannabis-europe","23":"tag-otc-cannabis-germany"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115146386044332194","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/397399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=397399"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/397399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/397400"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=397399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=397399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=397399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}